Back to search

University of Washington

Characterizing Alzheimer’s disease using quantitative proteomics

Abstract

dc:description.abstract

Alzheimer’s disease is characterized by the accumulation of neuropathologic amyloid-β and tau peptides in the brain. Bottom-up mass spectrometry proteomics methods were used to understand the protein landscape in the brains with different causes of Alzheimer’s. Correlating peptide abundances with amyloid-β tryptic peptides reveals additional subgroups of disease in sporadic Alzheimer’s cases, with differences across the four brain regions sampled. A cerebrospinal fluid targeted mass spectrometry assay for Alzheimer’s disease related proteins was developed as a proof-of-concept of an updated assay development workflow. This work demonstrates the feasibility of using peptide performance on high-resolution instruments to inform assay targets on a unit-resolution instrument. Both projects with Alzheimer’s disease demonstrate the importance of proteoforms in human disease, a fact that we argue should be considered more carefully when interpreting or developing bottom-up proteomics experiments.

Author and committee

dc:creator, dc:contributor.*
Author dc:creator
  • Plubell, Deanna Lisa
Advisor dc:contributor.advisor
  • MacCoss, Michael J

Subjects

dc:subject × 6

Rights

dc:rights
Statement dc:rights
  • CC BY
Language dc:language.iso
en_US

Identifiers

dc:identifier.*
Handle dc:identifier.uri
https://hdl.handle.net/1773/52046

Chain of custody

source
Harvested from
University of Washington
Base URL
digital.lib.washington.edu/server/oai/request
Last updated
2026-11-19
Source record
OAI-PMH GetRecord
citation

Plubell, Deanna Lisa. Characterizing Alzheimer’s disease using quantitative proteomics. 2024. https://hdl.handle.net/1773/52046